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Screening of CYP450 2C9 genetic polymorphism associated 
with Acenocoumarol sensitivity in DVT cases 
 
Abstract 
Background: Deep vein thrombosis is a life threatening disease and remains one of 
the leading causes of morbidity and mortality. Warfarin/Acenocoumarol are  
coumarin derivatives widely used as an anticoagulant for treating DVT patients with a 
narrow therapeutic index and wide inter – individual variability in dose requirement 
due to the genetic variation in CYP450 2C9 and VKORC1 and associated with the 
risk of thromboembolism or bleeding depending on underdosing or overdosing 
respectively.   
 
Aim: To screen the CYP450 2C9*2,*3,*4 and *5 genotypes associated with 
Acenocoumarol sensitivity in Indian DVT cases.  
 
Methods: Fifty cases with clinical evidence of DVT were selected after confirmed 
with Doppler study of affected limb from the inpatients of Madras Medical College 
and Rajiv Gandhi Government General hospital. Blood samples were collected and 
DNA was isolated from the blood by phenol chloroform extraction method. PCR 
amplification of CYP450 2C9 exon 1 and exon 4 were amplified using respective 
sequence specific primer pairs. PCR products were analysed by PCR-RFLP and direct 
sequencing.  
 
Conclusion: CYP450 2C9 genetic variants *2, *3, *4 and *5 were analyzed in 42 
cases successfully. Out of 42 samples analyzed 5 samples were found to be 
heterozygous for CYP4502C9 *2 variant. All other cases were found to carry wild 
type alleles. The cases having CYP450 2C9*2 heterozygous variant require decreased 
dose of warfarin by approximately 20-30% compared to CYP2C9 wild type 
individuals.  
 
Key words: DVT, WARFARIN, CYP450 2C9. 
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INTRODUCTION 
 
 Deep vein thrombosis is clotting of blood within the deep venous 
system such as femoral vein, popliteal vein and one of the leading causes of 
hospital morbidity and mortality. Lower extremity DVT may leads to 
pulmonary embolism, post thrombotic syndrome, paradoxical embolization 
or phlegmasia cerulae dolens which can result in major disability or death. 
Many Studies have shown that patients having chronic venous obstruction 
result in post thrombotic syndrome and that multi segment venous 
involvement and Ileofemoral obstruction lead to most profound morbidity(1) 
(2). 
       Oral anticoagulants like Warfarin/Acenocoumarol and other coumarin 
derivatives are widely used for DVT treatment. To determine the appropriate 
dose of oral anticoagulants is a challenge due to narrow therapeutic index and 
a wide inter-individual variability in dose requirement and patients may 
develop thromboembolism or bleeding associated with under-dosing or over-
dosing respectively.(3) 
      Warfarin is a “racemic mixture of R- warfarin and S-warfarin”. S-
warfarin is three to five times more potent in its pharmacodynamics effect 
than R-warfarin. CYP2C9 enzyme metabolizes S-Warfarin and CYP-450 
enzyme metabolizes R-Warfarin(4). By inhibiting the  vitamin K epoxide 
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reductase complex 1 (VKORC1), Warfarin  antagonizes functionally reduced 
vitamin K to be converted into oxidized  vitamin K, hindering the active 
clotting factors formation from premature clotting factors, causing an  
anticoagulation effect.  
         Studies have consistently shown the role of both genetic and non-
genetic factors in explaining the wide inter-individual variability in 
warfarin/Acenocoumarin dose. Genetic variation in the VKORC1 (drug 
target) and CYP2C9 (drug metabolizing enzyme) have been shown to 
account for 30-50% variability in the drug dose (4). 
Therefore studying the genotypes of CYP2C9 and VKORC1 in Deep 
Vein Thrombotic patient is of key importance for fixing the anti-coagulant 
dose to reduce the adverse side effects and for effective treatment. Since 
CYP2C9 is important for the clearance of the anticoagulant drugs from the 
system this pilot study aims to rule out the presence of defective allele 
frequency in South Indian population.  
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AIM AND OBJECTIVES 
 To screen the association of CYP450 2C9 genotypes to 
Acenocoumarol sensitivity in South Indian DVT cases. 
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REVIEW OF LITERATURE 
       Deep vein thrombosis is the presence of thrombus with accompanying 
inflammation in a vein. Venous thrombi are usually formed at the site of 
stasis. Role of platelet in the formation of venous thrombi is minimal. Venous 
thrombi usually occur in superficial or deep venous system of lower limb. 
Thrombi occurs in Superficial veins can cause congestion, swelling and pain. 
Deep vein thrombus is more prone for embolization. 
Fate of thrombus 
                Thrombi may propagate, resolve or embolize  
• Propagation of thrombus leads to vessel obstruction  
• Dislodge of fragment of thrombi distal to circulation is called 
embolization  
• Thrombi may be resolved due to endogenous  fibrinolytic  system 
 
Deep vein thrombosis (DVT) is the main cause of life threatening 
pulmonary embolism (PE). Most thrombi form in the deep calf veins – in the 
valve sinuses of the soleal veins or behind the valve cusps in the posterior and 
anterior tibial vein (the muscles of the calf and the thigh). It leads to pain 
and swelling in the leg and may cause serious complications like PE.  
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DVT and pulmonary embolism together are known as venous 
thromboembolism (VTE).  DVT in popliteal vein, femoral vein and iliac 
branches contributes to 20% of DVT incidences and 95% of pulmonary 
embolism.  Annual incidence is 1/ 1,000 worldwide is affected by DVT. So it 
is important to prevent proximal DVT that leads to fatal PE as a 
complication. 
In cases like Paget-Schrötter disease,  venous  thrombosis occurs in the 
upperlimb. “DVT and PE are two aspects of the disease known as venous 
thromboembolism”. 
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PATHOPHYSIOLOGY  
• Virchow first described the factors that predispose to DVT  in 1856 
Virchow traid-The three important factors that are essential for 
thrombus formation are  
 i) Stasis or turbulent blood flow,  
 ii) Endothelial damage 
 iii) Hypercoagulability 
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• complex interaction of congenital (inherited) factors and acquired risk 
factors determines individual risk 
Pelvic veins and IVC can be affected by extension of lower extremity DVT. 
Occasionally upper limb veins are involved when indwelling central venous 
catheter is placed for long duration and with the rare Paget schrotter disease.  
       The mechanism of arterial thrombosis causing acute coronary syndrome 
has been studied extensively than the mechanism of development of venous 
thrombosis. Formation of clots in the venous system occurs without any 
vessel wall damage, whereas vessel wall damage initiates coagulation in 
arteries. Tissue factor initiates venous thrombi formation which leads to 
conversion of prothrombin to thrombin, followed by fibrin deposition. 
Venous thrombi mainly composed of RBCs and fibrin and the fibrin attaches 
to endothelium of blood vessel. Other components are WBCs and platelets. 
Even though platelets are not significantly present as in arterial thrombus, 
they may play a role. VTE is associated with inflammation, and ‘WBCs play 
a role in the formation and resolution of venous clots’. 
           Often, Deep vein thrombosis forms in the venous valves. Hypoxemia 
in a valve sinus occurs due to blood flow pattern in the valves. Stasis in the 
venous system worsens hypoxemia, which activates pathways including HIF-
1 and early growth response protein 1. Low oxygen concentration leads to 
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reactive oxygen species production and activates NF-B which regulates HIF-
1 transcription.  HIF-1 and early-growth-response protein 1 contribute to 
monocyte association with  P-Selectin (endothelial proteins),  prompting 
monocytes to release tissue factor-filled microvesicles, which binds to the 
blood vessel wall and initiate clotting. 
 
 
 10   
 
 
 
CAUSES FOR DVT 
  Genetic and behavioral factors play a role in DVT. Deep vein 
thrombosis commonly occurs in elderly people above sixth decade, even 
though it occurs in all age groups. Having a family history of DVT in parents 
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or siblings can increase DVT risk.   Smoking and obesity are important risk 
factors in DVT formation. 
Venous thrombosis may develop when blood flow is slow or stasis occurs. 
Risk factors include (5, 6, 7, 8,9,10):    
• A pacemaker catheter that has been manipulated through the femoral 
vein. 
•  Bed ridden state 
• F/H of venous thrombosis 
• Pelvic fractures  
• 6 months following delivery 
• Obesity 
• Major surgeries involving pelvis, hip, knee. 
Other risk factors are 
• Malignancy 
• Autoimmune disorders, such as SLE 
• Smoking 
• Taking estrogens or contraceptive pills (higher  risk  with smoking) 
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• Long travels  
             The chances are more when there is one or more of the risk factors 
listed above. 
Inactivity- In case of inactivity for long time as in case of prolonged 
hospitalization, bed ridden state, or  long travel, blood pools in the lower 
extremities increases the risk of clot Injury or surgery involving lower 
extremities 
Genetics - In most cases the risk is only there if it is associated with at least 
one other risk factor. 
Pregnancy – risk increases in females with some inherited blood disorders. 
Cancer- risk is increased with cancers of pancreas, ovary, lung, urinary tract, 
breast, brain, stomach. 
Ulcerative colitis and other inflammatory bowel diseases 
Cardiac failure  
HRT in postmenopausal females  
Oral contraceptive pills  
Past history of deep vein thrombosis  
Obesity  
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Smoking  
Height – tall stature in males 
Central venous catheters  
Orthopedic casts  
SYMPTOMS 
Signs of DVT include 
 pain, 
 tenderness, 
 swelling and 
 Discoloration in the affected leg.   
DVT symptoms can be progressive. Typically symptoms will begin in 
one leg. Over the course of a few days, swelling and discoloration occur in 
that leg. Sometimes, the condition can go undetected because deep-vein 
blood clots in legs can be too small to trigger medical attention. 
Sometimes, patient presents with signs and symptoms of PE  
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• Acute onset breathlessness  
• Chest pain, at rest and on exertion 
• Hemoptysis 
• Wheezing 
• Syncope 
• Unexplained anxiety                    
• Tachycardia 
DIAGNOSIS 
      One or more special tests needed to rule out other problems or to confirm 
a diagnosis. 
The two tests that are often done first to diagnose a DVT are: 
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• D-dimer blood test 
• Doppler ultrasound exam of the legs  
Criteria for diagnosis 
DVT – use of Wells clinical prediction rule in establishing  
Pre- test probability 
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Other clinical prediction rules include charlotte and Genewa / modified 
Genewa 
Other blood tests are following: 
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D-Dimer Test: D-Dimer presents in the circulation in small quantities 
normally. During the process of clotting it is produced as a breakdown 
product .Hence, it’s presence suggest the increased clotting activity in the 
body. 
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Principle of test: 
 
 
Human blood plasma usually does not have D-dimers. Activation of 
coagulation system produces them in blood. The D-dimer assay depends on 
the binding of a monoclonal antibody to a particular epitope on the D-dimer 
fragment. The commercially available kits rely on a different monoclonal 
antibody against D-dimer. The binding of the antibody is measured 
quantitatively quantitative measurement of antibody binding is done by one 
of various laboratory methods. 
Detection of evidence of thrombus within the circulation: D-dimer 
        A D- dimer measured by enzyme-linked immunosorbent assay (ELISA) 
below a cut-off of 300 to 540 ng/ml (the values differ slightly from one study 
to another) make the diagnosis of DVT (or PE) unlikely. However, a 
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concentration of D-dimer above the cut-off level is not useful for making a 
positive diagnosis because of the large number of false positive tests. 
 
        Conventional ELISA assays are cumbersome and not suited for 
emergency use, which limited the practical utility of D-dimer measurements 
until the development of rapid ELISA assays. These provide the best balance 
of sensitivity and specificity among the various assays for the safe diagnostic 
handling of patients with suspected DVT and PE. 
 
  Activated protein C resistance (APCR)  
 
            Antithrombin III is a blood test that measures the amount of 
antithrombin III (AT III), and risk of thrombosis occurs when there is 
deficiency of AT III in blood, or it is less active. 
Lupus anticoagulants are antibodies against substances in the lining 
of cells. These substances prevent blood clotting in a test tube. They are 
called phospholipids. Persons with these antibodies may have an abnormally 
high risk of blood clotting. 
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Duplex ultrasound:  Painless and non-invasive, ultrasound tests 
require no radiation but require a skilled person to obtain accurate results. 
The drawback of this test is less sensitive in finding pelvic thrombosis which 
are deeply situated. 
Venography: Detection of the physical presence of thrombus in leg veins. 
The ‘gold standard’ is contrast venography, but this can be unpleasant for 
patients, time consuming for radiology departments, and expensive. This has 
driven the search for acceptable noninvasive methods of diagnosis and 
contrast venography is now rarely performed, except as part of research 
protocols. In most centres contrast venography has been replaced by B-mode 
ultrasonography as the preferred first line diagnostic technique.  
 
Magnetic resonance imaging (MRI): This is useful in finding out 
deeply situated pelvic thrombus.  
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COMPLICATIONS 
Other complications by PE 
  Palpitations 
 Cardiac failure or cardiogenic shock 
 Breathing difficulties 
 Pulmonary hypertension. 
Other rare DVT Complications include: 
            Renal vein thrombosis 
  Heart attack 
  Stroke 
 It is important to treat pulmonary embolism immediately. 
TREATMENT 
Surgical intervention for DVT is needed in rare cases like large clot 
obstructing a major blood vessel, causing severe symptoms. But, Surgery 
itself increases the risk of new thrombus formation. 
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Goals of Treatment for DVT to prevent 
  Extension of thrombus. 
  embolism formation 
  complications like post thrombotic syndrome such as leg pain and 
swelling 
  recurrences 
  Medical management for DVT 
      DVT and PE are aspects of the same disease-VTE. Forty percent of 
patients with DVT without clinical evidence of PE have evidence of emboli 
on lung scanning. The principles of therapeutic coagulation are the same for 
both. In proximal DVT and PE this has involved immediate anticoagulation 
with heparin followed by a period of warfarin. Distal DVT can be managed in 
the same way, but an alternative strategy is to use serial noninvasive testing 
which only reliably detects proximal thrombosis, to ensure that suspected 
distal thrombosis does not extend above the knees, withholding treatment if it 
does not. 
There is clear evidence that immediately acting anticoagulation is 
needed in the initial phase and that anticoagulation with oral vitamin K 
antagonists alone is inadequate. Warfarin can be commenced on the first day 
and heparin is continued for 5 days or until the INR is greater than 2.0 for 2 
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consecutive days, whichever is the longer. Extending the period of 
heparinization from 5-10 days is not more effective and increases the risk of 
HIT. However, massive PE or severe iliofemoral thrombosis a long period of 
heparin therapy may be considered(11). A 3 to 6-month course of warfarin 
oral tablets is also prescribed to prevent a recurrence of DVT. For those with 
recurrent DVTs, anticoagulant medication is usually taken for lifelong. 
Surgical intervention for DVT is needed in rare cases like large clot 
obstructing a major blood vessel, causing severe symptoms. But, Surgery 
itself increases the risk of new thrombus formation. In open surgical 
thrombectomy, complete removal of thrombus from the affected veins is 
done. This procedure needs multiple incisions and procedural maneuvers, like 
balloon embolectomy, irrigation and creation of arteriovenous fistula, and 
still this may end in failure. Patients are at risk of wound complications and 
later they may need arteriovenous fistula ligation. But underlying etiology is 
not corrected. So, it has limited role in the acute DVT management. For this 
reason, surgical intervention is resumed for patients with extensive DVT and 
Phlegmasia(11,12). 
Thrombolysis - TPA (tissue plasminogen activator) is used for this 
procedure. Due to serious side effects like bleeding, they are used only the 
life is at risk. 
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Inferior vena cava filter -Tiny umbrella-like device is used to filter 
venous thrombus. So that venous flow is maintained normally. 
 
 
 
 
 
Catheter directed thrombolysis (clot busting) treatment: 
It is done by interventional radiologists under imaging guidance. It is 
designed for immediate lysis of clot, restoring blood flow immediately, 
preserving valve function and minimizing complications. Thrombolysis is 
done after placing the tip into the clot. Venography is done to look for 
narrowing of the vein and balloon angioplasty or stent placement is done with 
interventional radiologist. 
Compression stocking – which helps to reduce pain and swelling. It 
also prevents the development of long term DVT complications like post-
thrombotic syndrome. 
 
Inferior vena cava filter 
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DRUGS USED TO TREAT DVT 
HEPARIN (UH) 
It is a highly sulfated glycosaminoglycan, which is as an injectable in 
the treatment of DVT and PE. It is also used in the treatment of ischemic 
heart disease, cerebrovascular accidents like stroke and CVT. 
Mast cells store heparin as secretary granules and tissue injury releases 
heparin into the circulation as a defense mechanism. Heparin sulphate 
proteoglycans derived from endothelial cells play a role in anticoagulation. 
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MECHANISM OF ACTION 
                                     Heparin administration 
                                         Heparin binds to Antithrombin III 
                        Reactive site loop flexibility increases 
                        AT becomes 1000 fold more active 
                   Inhibition of the activated coagulation factor         
     which include Thrombin, factor Xa,  factor IXa, IXa, XIIa,XIIIa 
 
HEPARIN METABOLISM (13) 
Saturable mechanism                                       Unsaturable mechanism 
Through RE system and endothelial cells             Excreted through kidney 
To which heparin binds with high affinity           - 
Acts in low dose                                                   Acts in higher dose        
WARFARIN  
 Campell and Link (1939) identified bishydroxycoumarin 
(Dicoumarol). A synthetic congener, a potent rodenticide was developed in 
1948. 
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The oral vitamin K antagonists have been the mainstay of long term 
anticoagulant therapy. Warfarin is the commonest antagonist given. 
Acenocoumarol having shorter half-life and Phenindione also are used. 
Warfarin takes a number of days to become effective, during which period 
heparin is given. When warfarin is started, the vitamin K dependent factors 
fall according to their half-lives. Factor VII and protein C have the shortest 
half-lives, so that despite a prolongation of the INR due to factor VII 
deficiency, warfarin may initially be procoagulant. This is the mechanism for 
the rare problem of warfarin induced skin necrosis most often described on 
those with protein c deficiency(14).     
 
Chemistry 
 Warfarin is the prototype of anticoagulant. Numerous anticoagulants 
have been synthesized as 4-hydroxycoumarin derivatives and of the related 
compound indan-1’3-dione.Only coumarin derivatives are used widely. The 
4-hydroxy coumarin residue, with a nonpolar carbon substituent at the 
position 3, is the minimal structural requirement for activity. This carbon is 
asymmetrical in warfarin and in phenprocoumarin and acenocoumarol. 
 
 The R-and S-enantiomers differ in anticoagulant potency, metabolism, 
elimination, and interactions with other drugs. Commercial preparations of 
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the anticoagulants are racemic mixtures. No advantage of administering a 
single enantiomer has been established. 
Mechanism of action 
 The oral anticoagulants act indirectly by interfering vitamin K 
dependent clotting factors synthesised in liver. They block the active 
hydroquinone form of vitamin K regeneration, the cofactor required for 
gamma-carboxylation of glutamate residues of prothrombin and factor VII, 
IX, X. Carboxylated factors then bind to Ca 2+ and coagulation sequence 
proceeds. During gamma carboxylation, active vitamin K is oxidized to an 
epoxide, which must be reduced back to vitamin K hydroquinone to become 
active once again by the enzyme vitamin K reductase. This enzyme is 
inhibited by oral anticoagulants. S- warfarin is metabolized by CYP2C9. 
Common genetic  polymorphism in this enzyme can influence warfarin 
metabolism. Polymorphisms in the C1 subunit of vitamin K reductase 
(VKORC1) also can affect the susceptibility of the enzyme to warfarin 
induced inhibition, thereby influencing warfarin dosage requirements(15, 16). 
 
 Congenital defeciencies of the procoagulant proteins to these levels 
cause mild bleeding disorders. It takes some days to attain full antithrombotic 
effect of Warfarin, as the t1/2 of factor II is longer. But PT will be prolonged 
immediately after administration because of the shorter half-life of factor VII 
that is rapidly reduced. 
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The approximate t1/2 in hours follows 
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Dosage 
 The usual adult dosage of warfarin is 2-5mg for 2-4 days followed by   
1-10 mg as indicated by measurements of the International Normalised Ratio 
(INR) a value derived from the patient’s PT. As indicated later common 
genetic polymorphisms render patients more or less sensitive to warfarin. A 
lower initial dose should be given to the patients with increased risk of 
bleeding, including the elderly. Warfarin is administered orally. Age 
correlates with increased sensitivity to the drug. Warfarin can also be given 
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intravenously without dose modification. Intramuscular injection is not 
recommended because of the risk of hematoma formation. 
 
Absorption 
 The bioavailability of warfarin is nearly complete when the drug is 
administered orally, intravenously or rectally. Repeated skin contact with the 
solution of warfarin used as a rodenticide may cause bleeding. Food can 
decrease the rate and extent of absorption. Warfarin usually is detectable 
within one hour of its oral administration and concentration peak in 2-8 
hours. 
 
Distribution 
 Warfarin is binding almost completely to plasma proteins, principally 
albumin, and the drug is rapidly distributed into the albumin space.   Foetal 
plasma concentrations approach the maternal values, but active warfarin is 
not found in milk (unlike other coumarins and idandiones). Therefore, 
warfarin can safely be administered to nursing mothers. 
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Warfarin Metabolism 
 
 
 
 Warfarin is administered as a racemic mixture of R-S warfarin. S-
warfarin is 3-5 folds more potent than R- warfarin and is metabolized 
principally by CYP2C9. 
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 Individuals with the CYP2C9*2 and CYP2C9*3 polymorphisms have 
decreased clearance of S-warfarin and therefore also an increased plasma 
concentration ratio when compared to R-warfarin. In patients with allelic 
variants the relative concentration of S-warfarin increases in patients 
homozygous for the CYP2C9*3 polymorphisms(14,15).  
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          CYP2C9 and VKORC1 single nucleotide polymorphisms causes 
variable response to warfarin. The enzyme encoded by CYP2C9 is associated 
with reduced activity and decreased requirement of drug dose 
             Inactive warfarin metabolites are excreted in urine and stool. The 
average rate of clearance from plasma is 0.045 ml/mt/kg. The t1/2 varies (25-
60 hours) with a mean of 2-5 days. 
 
Drug and other interactions 
Factors that cause a decreased effect of oral anticoagulants include: 
• Reduced drug  absorption by  cholestyramine which binds with the 
drug in the GI tract 
• Increased distribution volume and a short t1/2 secondary to 
hypoproteinemia as in nephrotic  syndrome 
• Enzyme inducers like  barbiturates, carbamazepine or rifampin 
•  vitamin K rich foods or supplements 
• Pregnancy 
 
The PT can be shortened in any of the above cases. 
Many drugs interact with warfarin. Such that patient education and 
constant vigilance are essential. Close monitoring of the INR is advised when 
concomitant medication is altered. 
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      Relative deficiency of vitamin k may result from inadequate diet (eg: 
postoperative patients on parental fluids) especially when coupled with the 
elimination of intestinal flora by antimicrobial agents. Vitamin k gut bacteria 
are an important source of this vitamin. In addition to an effect on reducing 
intestinal flora, cephalosporin containing heterocyclic side chains also 
inhibits steps in the vitamin cycle. Low concentrations of coagulation factors 
may result from impaired hepatic function, congestive heart failure or hyper 
metabolic states such as hyperthyroidism. Elderly patients are more sensitive 
to oral anticoagulants. 
 
Resistance to warfarin 
• (Some patients require>20 mg/d of warfarin to achieve therapeutic 
INR). 
• Excessive vitamin K intake from the diet or parental 
supplementation. 
• Noncompliance  
• Laboratory error  
• Hereditary warfarin resistance  
• Mutations in the VKORC1 gene  
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   Sensitivity to warfarin 
Approximately 10% patients require <1.5 mg/d of warfarin to achieve 
an INR target of 2-3. As indicated earlier these patients often possess variant 
alleles of CYP2C9 or variant VKORC1 haplotype, which affect the 
pharmacokinetics or pharmacodynamics of warfarin respectively (daly and 
King,2003). 
Adverse effects 
Bleeding 
 Incidence is <3% per year in patients treated with a target INR of 2-3. 
Risk factors for bleeding are increasing age, a history of stroke, a history of 
gastro intestinal bleed, anemia, renal impairment, diabetes, and recent MI. A 
major problem is in the starting and stopping of other medication.  The ICH 
risk increases dramatically with an INR >4, especially in elderly people. In a 
large outpatient anticoagulation  clinic, the most common factors associated 
with a transient elevation of the INR to a value of >6 were uses of a new 
medication known to potentiate warfarin (eg;acetaminophen)(17), advanced 
malignancy, recent diarrhoeal illness, and   taking more warfarin than 
prescribed. Patients must be informed of the signs and symptoms of bleeding 
and laboratory monitoring should be done at frequent intervals during 
intercurrent illnesses or any change or medication or diet. 
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 If the INR is  above the therapeutic range but <5 and the patient is not 
bleeding or in need of a surgical procedure, warfarin can be discontinued 
temporarily and restarted at a lower dose once the INR is within the 
therapeutic range (15). If the INR is more  or  equal to 5, vitamin K 
(phytanadione) can be given orally at a dose of 1-2.5mg (for 5-9) or 3-5mg 
(for INR>9). Then doses of oral vitamin K generally cause the INR to fall 
substantially within 24-48 hours without rendering the patient resistant to 
further warfarin therapy. Higher doses or parenteral administration may be 
required if more rapid correction of the INR is necessary. The effect of 
vitamin K is delayed for at least several hours because reversal of 
anticoagulation requires synthesis of fully carboxylated   coagulation   
factors. If immediate  hemostatic competence is necessary because of serious 
bleeding or  profund  warfarin  overdosage (INR>20), adequate concentration 
of vitamin K dependent coagulation factors can be restored by transcription 
of fresh frozen plasma (10-20ml/kg) supplemented with 10 mg of vitamin K, 
given by intravenous infusion. Transfusion of plasma may need to be 
reported because of transfused factors (particularly Factor VII) are cleared 
from the circulation more rapidly than the residual oral anticoagulant. 
Vitamin K administered intravenously carries the risk of anaphylactoid 
reaction and therefore should be used cautiously and administered slowly. 
Patients who receive high doses of vitamin K may become unresponsive to 
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warfarin for several days, but heparin can be used if continued 
anticoagulation is required. 
Birth defects 
Abortions 
Nasal hypoplasia and stippled epiphyseal calcifications 
CNS abnormalities 
Foetal or neonatal haemorrhage 
Intrauterine death 
Vitamin K antagonists should not be used during pregnancy, but, 
Heparin, LMWH, or fondaparinux can be used safely in this circumstance. 
 
Skin necrosis 
Warfarin induced skin necrosis is a rare complication charecterized 
by the appearance of skin lesions 3-10 days after treatment is initiated. The 
lesions typically on the extremites, but adipose tissue, the penis and the 
female breast also may be involved. Lesions are charecterized by widespread 
thrombosis of the microvasculature and can spread rapidly in response to the 
initial dose of vitamin k antagonists. It has been proposed that the dermal 
necrosis is a manifestation of a temporal imbalance between the anticoagulant 
protein C and one or more of the procoagulant factors and is exaggerated in 
patients who are partially deficient in protein C or protein S. However, not all 
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patients with heterozygous deficiency of protein C or protein S develop skin 
necrosis when treated with warfarin, and patients with normal activities of 
these patients can also be affected. Morphologically similar lesions can occur 
in patients with vitamin k deficiency. 
  
Other toxicities 
Purple toe syndrome after 3-8 weeks of therapy 
Other infrequent reactions include alopecia, urticaria, dermatitis, fever, 
nausea, diarrhoea, abdominal cramps, and anorexia. 
“Warfarin can precipitate the syndromes of venous limb gangrene and  
multicentric skin necrosis when given to patients with heparin induced 
thrombocytopenia who are not receiving a parenteral anticoagulant” 
(Warkentin 2003). 
 
Clinical use 
Vitamin K antagonists are used to prevent the progression or 
recurrence of acute DVT or pulmonary embolism following an initial course 
of heparin. As per Geerts et al., 2008, “they also are effective in preventing 
venous thromboembolism in patients undergoing orthopaedic or 
gynaecological surgery, recurrent coronary ischemia in patients with acute 
myocardial infarction, and systemic embolization in patients with prosthetic 
heart valves or chronic atrial fibrillation. Specific recommendations for oral 
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anticoagulant use for these indications have been reviewed”. “A higher target 
INR (eg; 2.5-3.5) generally is recommended for patients with high risk 
mechanical valve” (Hirsh et al 2003)(18). 
 
         For treatment of acute thromboembolism, Heparin, LMWH, or 
fondaparinux usually is continued for atleast 5 days after warfarin therapy is 
begun and until the INR is in the therapeutic range on two consecutive days. 
This overlap allows for adequate depletion of the vitamin K dependent 
coagulation factors with long half -life especially factor II. Frequent INR 
measurements are indicated at the onset of therapy to guard against excessive 
anticoagulation in the unusually sensitive patient. The testing interval can be 
lengthened gradually to weekly and then monthly for patients on long term 
therapy whose test results have been stable. 
 
Initiation of anticoagulation with warfarin 
               The INR equals (PT/MNPT)ISI where MNPT is the (mean normal) 
control PT and ISI is the international sensitivity index of the thromboplastin 
and used in the assay. For the treatment of DVT and PE, target INR should be 
2.5 (range 2.0 to 3.0). 
 
If the initial coagulation tests are not prolonged, it has been customary 
to start 10mg of warfarin or 2mg of Acenocoumarol the first day evening and 
check the INR the following morning, adjusting the dose according to the 
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daily INR results until the INR is stable. When INRs are stable they may go 
for up to 8 weeks between INR checks. If the INR is unstable patients are 
seen more frequently, but it should be noted that with 
warfarin/Acenocoumarol it takes approximately one week (5times the half-
life) to reach a new study state after dose adjustment, hence more frequent 
dosage alteration is inadvisible.          
  
 
Monitoring Anticoagulant Therapy: The INR (International  
Normalized Ratio) 
           To monitor therapy, a blood sample is obtained, and the PT is 
determined along with that of a sample of normal pooled plasma. Formerly, 
the results were reported as a simple ratio of the two PT values. However, 
this ratio can vary widely depending on the thromboplastin reagent and the 
instrument used to initiate and detect clot formation. The PT is prolonged 
when the functional levels of fibrinogen, factor V, or the vitamin K-
dependent factors II, VII, or X are decreased. Reduced levels of factor IX or 
proteins C or S have no effect on the PT. PT measurements are converted to 
INR measurements by the following equation:  
where INR = international normalized ratio 
ISI = international sensitivity index 
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          The ISI value, supplied by the manufacturer of the regent, indicates the 
relative sensitivity of the PT (determined from a given batch of 
thromboplastin) to decreases in the vitamin K-dependent coagulation factors 
in comparison with a World Health Organization human thromboplastin 
standard. Reagents with lower ISI values are more sensitive to the effects of 
vitamin K antagonists (i.e., the PT is prolonged to a greater extent in 
comparison with that obtained with a less-sensitive reagent having a higher 
ISI). Ideally, the ISI value of each batch of thromboplastin should be 
confirmed in each clinical laboratory using a set of reference plasmas to 
control for local variables of sample handling and instrumentation. 
          As per Moll and Ortel, 1997, “The INR does not provide a reliable 
indication of the degree of anticoagulation in patients with the lupus 
anticoagulant, in whom the PT and other phospholipid-dependent factors are
prolonged at baseline. In these patients, a chromogenic factor X assay or the 
prothrombin-proconvertin time assay may be used to monitor therapy” 
 
 
 PHARMACOGENETICS OF WARFARIN 
 Souto JC et al., 2000 says, “Single nucleotide polymorphisms in the 
cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKOR) 
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genes have been shown to have a significant effect on warfarin dose 
requirement”(19). 
 
“Warfarin is administered as a racemic mixture of (S) and (R) 
warfarin”.    As per NA Limdi et al., 2008 “S-warfarin is metabolized by 
CYP2C9 and CYP2C8, CYP2C18, CYP2C19 serving as minor pathways. R-
warfarin is mainly metabolized by CYP1A2 and CYP3A4 with CYP1A1, 
CYP2C8, CYP2C18, CYP2C19 and CYP3A4/5 serving as minor 
pathways”(20) 
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CYTOCHROME P450 GENES 
Cytochrome P450 genes produce enzymes that are involved in the 
synthesis and metabolism of various molecules and chemicals within cells 
metabolize external substances, such as drugs that are ingested and internal 
substances, such as toxins that are formed within cells. There are 
approximately 60 CYP genes in humans. 
Larsen TB et al., 2003 says “Common variations (polymorphisms) in 
cytochrome P450 genes can affect the function of the enzymes. Depending on 
the gene and the polymorphism, drugs can be metabolized quickly or slowly. 
If a cytochrome P450 enzyme metabolizes a drug slowly, the drug stays 
active longer and less is needed to get the desired effect. A drug that is 
quickly metabolized is broken down sooner and a higher dose might be 
needed to be effective”(21). Cytochrome P450 enzymes account for 70 to 
80% of enzymes involved in drug metabolism. 
CYP GENE FUNCTIONS 
These enzymes are divided into two major groups 
• "Steroidogenic CYP enzymes” 
• "Xenobiotic CYP enzymes” 
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CYP2C9 Gene (cytochrome P450, family 2, subfamily C, polypeptide 9) 
Location: 
10q24 
Sequence: 
Chromosome: 10; NC_000010.10 (96698415..96749148)  
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Chromosome10-
NC_000010.10
  
 
“The CYP2C9 gene is located on the long (q) arm of chromosome 
10 at position 24 from base pair 96,698,414 to base pair 96,749,147”. 
 
 
“The human cytochrome CYP2C9 gene spans a region of 
approximately 55 kilobases and is composed of nine exons” (De Morais et 
al., 1993). The gene resides on chromosome 10 (q24) and is clustered among 
other closely related 2C-genes in the order: Cen-2C18-2C19-2C9-2C8-Tel. 
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Three distinguishable phenotypes based on drug metabolism efficiency are 
estimated by genotypes. 
 
 
 
      Souto JC et al., 2000)says, “ Changes in the amino acid sequence of 
CYP2C9 can affect both the activity and substrate specificity of CYP2C9. 
Previously, three alleles were identified in the Caucasian 
population: CYP2C9*1, CYP2C9*2 and CYP2C9*3”(19). 
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Gene Variant Allele Protein change Effect 
CYP2C9 C.430C>T *2 R144C Decreased 
activity 
CYP2C9 C.1075A>C *3 I345L No activity 
 
 The CYP2C9*1 allele 
• encodes the wild-type protein 
• Most common allele of 30 Cyp2C9 alleles 
 CYP2C9*2 allele  
• Contains a C-to-T transition, 
• Leading to substitution of cysteine by arginine at amino acid position 
144 
• Only having 70%activity 
 The CYP2C9*3 allele  
• Defined by an A-to-C nucleotide substitution  
• Substitution of leucine by isoleucine at amino acid position 359 
• Having 20% activity 
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 Both *2, *3 variant alleles are associated with significantly reduced 
enzyme activity (23,24). 
SNPs often lead to the formation of different alleles of a gene. Of the 
30 CYP 2C9 alleles discovered, CYP 2C9*2 (or 430 C>T) and CYP 2C9*3 
(1075A>C) are the two alleles that are considered strong risk factors for over 
anticoagulation. 
Patients who are carriers of these two alleles (*2 and *3) metabolize S-
warfarin more slowly in vivo, which results in the need for lower warfarin 
maintenance doses, compared with patients who carry the wild-type allele 
(20) . 
    Allele      Ethnicity        Frequencies 
     *2         Caucasians      10-20% 
                  Asians               1-3% 
                 Africans             0-6% 
    *3         allele 
• Less common 
• <10% in all population 
• Rare in African population 
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INFLUENCE OF CYP2C9  ON WARFARIN DOSE 
            As per Goodman and Gillman et al., “Patients with wild-type 
CYP2C9 genotype need approximately 6 mg/day, those with two copies of 
the *2 variant have an average daily dose of 4 mg/day and those with two 
copies of the *3 variant have an average daily dose of about 1.5 mg/day”. 
 
CYP2C9 Genotypes warfarin dose 
Wild  type 6mg/d 
2 copies of *2 variant 4mg/d 
2 copies of *3 variant 1.5mg/d 
 
  As per NA Limdi et al., 2008 “Among African Americans, CYP2C9 
genotype has not demonstrated a consistent influence on warfarin dose.  In 
Asian populations, CYP2C9*3 has been shown to be associated with lower 
dose requirements. NA Limdi et al provide a synthesis of data from studies 
that have evaluated the influence of both CYP2C9 and VKORC1 on warfarin 
dose”(20).  
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VITAMIN K EPOXIDE REDUCTASE COMPLEX, SUBUNIT 1 
‘VKORC1 (vitamin K epoxide reductase complex, subunit 1) is a 
protein-coding gene’. Reduced vitamin K is the active form and required for 
the carboxylation of glutamic acid residues in some blood-clotting proteins. 
The product of this gene encodes the enzyme that is responsible for reducing 
vitamin K 2, 3-epoxide to the enzymatically activated form(21,22). Two 
pseudo genes have been identified on chromosome 1 and the X chromosome .  
Location: 
16p11.2 
 
Sequence: 
Chromosome: 16; NC_000016.9 (31102175..31106699, complement) 
Chromosome 16 - 
NC_000016.9
 
 
  
 54   
 
Warfarin works by noncompetitively inhibiting VKORC1 thus blocks 
the clotting cascade. Many polymorphisms in VKORC1 that influence 
warfarin dosing have been identified. The most commonly studied SNPs of 
VKORC1 include the 1173 C>T (CC is the wild-type) and 1639 G>A alleles 
(GG is the wild type). They are associated with a lower level of expression of 
VKORC1 because of their decreased translation of mRNA into 
proteins(25,27). 
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 “These AA, AB, and BB haplotypes are associated with low, 
intermediate, and high warfarin maintenance doses, respectively”.  
CYP2C9 AND VKORC1 EFFECT ON WARFARIN   DOSING 
Lee C.R et al., 2000 shows, “Variability in CYP2C9 and VKORC1 
alleles are associated with increased sensitivity to warfarin”(22).  
As per Thomas P. Moyer et al., 2009, “The allelic variants found to 
affect warfarin sensitivity are 
 CYP2C9*1*1-VKORC1BB (less warfarin sensitivity than typical);         
CYP2C9*1*1-VKORC1AA (considerable variance in INR throughout 
initiation); 
 CYP2C9*1*2-VKORC1AB (more sensitivity to warfarin than 
typical); 
 CYP2C9*1*3-VKORC1AB (much more sensitivity to warfarin than 
typical); 
 CYP2C9*1*2-VKORC1AB (much more sensitivity to warfarin than 
typical); 
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 CYP2C9*1*3-VKORC1AA (much more sensitivity to warfarin than 
typical);  and CYP2C9*2*2-VKORC1AB (much more sensitivity to warfarin 
than typical)”(26,27,28) . 
GENOTYPE/ 
HAPLOTYPE 
CAUCASIANS AFRICAN 
AMERICANS 
ASIANS DOSE REDUCTION 
COMPARED WITH 
WILD-TYPE (%) 
CYP2C9           
  *1/*1 70 90 95 — 
  *1/*2 17 2 0 22 
  *1/*3 9 3 4 34 
  *2/*2 2 0 0 43 
  *2/*3 1 0 0 53 
  *3/*3 0 0 1 76 
VKORC1           
  Non-
A/Non-A 
37 82 7 — 
  Non-A/A 45 12 30 26 
  A/A 18 6 63 50 
 
Polymorphisms in two genes, CYP2C9 and VKORC1 (vitamin K epoxide 
reductase complex, subunit 1) account for most of the genetic contribution to 
the variability in warfarin response. CYP2C9 variants affect warfarin 
pharmacokinetics, whereas VKORC1 variants affect warfarin 
pharmacodynamics. Common variations in the CYP2C9 gene (designated 
CYP2C9*2 and *3), encode an enzyme with decreased activity, and thus are 
associated with higher drug concentrations and reduced warfarin dose 
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requirements. At least one variant allele of CYP2C9*2 or CYP2C9*3 is 
present in 25% of European-Americans, but these variants are relatively 
uncommon in African-American and Asian populations (Table 30–2). 
Heterozygosity for CYP2C9*2 or *3 decreases the dose of warfarin required 
for anticoagulation by approximately 20-30% compared with "wild type" 
individuals (CYP2C9*1/*1). Homozygosity for CYP2C9*2 or *3 can 
decrease the warfarin dose requirement by approximately 50-70%. Generally, 
the *3 allele has a greater effect than the *2 allele(35). 
 
White people show considerable variance in CYP2C9 allele types, 
whereas people of Asian or African descent infrequently carry CYP2C9 
allelic variants.  
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METHODS AND MATERIALS 
Study centre  
Institute of Internal Medicine, Madras Medical College and Rajiv 
Gandhi Government General Hospital, Chennai  
 
Study design  
Case control study  
 
Duration of the study  
6 months  
 
Sample  
 Fifty subjects with clinical evidence of Deep vein thrombosis were 
selected after applying inclusion & exclusion criteria from the inpatients of 
Internal Medicine and Vascular Surgery departments of Madras Medical 
College and Rajiv Gandhi Government General Hospital, Chennai  
 
Inclusion criteria 
Patients aged between >18 of both gender with confirmed Deep Vein 
Thrombosis. 
 
Exclusion criteria  
Use of a fibrinolytic agent to treat the current episode of DVT and/or PE 
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Liver diseases and renal failure 
Haematological disorders 
 
Methodology  
All cases were subjected to a detailed history taking and clinical 
examination based on a simple questionnaire which included complaints like 
pain, swelling, discoloration of lower limb, PT/INR and Doppler study of 
affected lower limb done. 
Collection of samples 
The cases recruited for this study were confirmed DVT cases based on 
clinical features and Doppler study. The study was explained to the patient in 
detail and informed consent was obtained. Detailed clinical parameters were 
collected from case records. Five ml of blood sample was collected from the 
patient in EDTA coated vacutainer tubes and transported on ice to lab. 
Reagents 
Tris      1M (PH 8.0) 
EDTA 0.5 (PH 8.0) 
TE (PH 8.0) (10 mM Tris, 1mM EDTA) 
RBC lysis buffer 
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WBC lysis buffer 
TAE 1x 
Proteinase K 
Phenol: chloroform:isoamyl alcohol 
  
DNA isolation  
DNA isolation was carried out by classical Proteinase K digestion and 
Phenol: chloroform : isoamyl alcohol method as described by Maniatis et 
al.,(1982). The blood sample was centrifuged at 3500rpm for 15min and the 
buffy coat which contains WBC was separated and was transferred to 2ml of 
centrifuge tube.  To remove the residual RBCs 1ml of 1x RBC loses buffer 
was added and incubated for 15 min at 37˚C. The sample was centrifuged at 
4000rpm for 5 min at room temperature and the supernatant was discarded. 
The cell pellet was washed with RBC lysis buffer for two more rounds. To 
the cell pellet, 500 µl of WBC lysis buffer, 5 µl of Proteinase K (1mg/ml) and 
10% SDS 25 µl (Final concentration 1%) was added and mixed well. The 
tubes were incubated at 37˚C for overnight in water bath. After the incubation 
period Phenol: Chloroform: Iso-proponal (25:24:1) mix was added to the 
clear lysate and mixed well until it forms a milky solution. The mixture was 
centrifuged at 12000 rpm for 20 min at 4˚C. The upper aqueous phase which 
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contains the DNA was transferred to a new 2 ml centrifuge tube using wide 
bore pipette. One more PCI extraction and two chloroform:isoamyl alcohol 
extraction was done to clear the protein and residual phenol. The aquous 
phase was transferred to a new tube and to this 2 volume of absolute ethanol 
was added. The tubes were inverted gently till DNA thread appears. The 
DNA was collected by spooling or pelleted by spinning at 12000rpm for 10 
mins at 4˚C. The supernatant was discarded and 1 ml of 70% ethanol was 
added to the DNA pellet to wash the residual salt and centrifuged for 12000 
rpm for 10 mins at 4˚C. The supernatant was discarded and the DNA pellet 
was air dried. The DNA was dissolved in appropriate amount of 1X TE 
buffer and stored in 4˚C. The isolated DNA was quantified in UV 
spectrometer. 
 
CYP2C9 Genetic polymorphism to be analyzed in this study 
Gene 
Allele 
variants 
SNP ID Base position 
CYP2C9 
*2 rs1799853 430C>T 
*3 rs1057910 1075A>C 
*4 rs1057909 1076T>C 
*5 rs28371686 1080C>G 
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PCR amplification 
CYP2C9 exon1 covering the*2 variability and exon 4 region that is 
having variant *3,*4,*5 were amplified using the forward and reverse primers 
in 20 µl reaction with 100 ng of template DNA. The reaction conditions and 
temperature cycling parameters were as follows: 
PCR reaction mix  
PCR content For 10µl 
reaction 
Final 
Concentration 
10X PCR buffer 1 1X 
25mM MgCl2 0.6 1.5mM 
2.5µM dNTPs 0.4 100µM 
2µM Forward 
primer 
0.3 60nM 
2µM Reverse 
primer 
0.3 60nM 
Taq Pol 0.05 0.02U 
D. H2O 6.17 - 
Template DNA 1 100ngm 
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Thermal cycling parameters 
 
 
 
The PCR product was run in 2% Agarose with 0.5X TAE at 100 Volt. 
 
Primers used to amplify CYP2C9 exon 1 region to study *2 variant 
 
>chr10:96701876+96702348 473bp  
CATGGCTGCCCAGTGTCAGCttcctctttcttgcctgggatctccctcctagtttcgtttctcttcc
tgtta 
ggaattgttttcagcaatggaaagaaat 
ggaaggagatccggcgtttctccctcatgacgctgcggaattttgggatg 
gggaagaggagcattgaggacC*2gtgttcaagaggaagcccgctgccttgt 
ggaggagttgagaaaaaccaa gggtgggtgaccctactccatatcactga 
ccttactggactactatcttctctactgacattcttggaaacatttcagggg 
72 ˚C 72˚C 
4˚C 
∞ 
7 min 
X ˚C 
94˚C 94˚C 
5 min 30 sec 
30 sec 
30 sec 
40 Cycles 
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tggccatatctttcattatgagtcctggttgttagctcatgtgaagcgggggtttgaagctgagagccaagggaa
tttgcacatatttgtgctgtgtg 
tgtacaggcatgattgtgcgtacagtgtgggtataaaaggttcatttaaTCCCATGTT 
CTCCTGAACTTTGCT 
 
 Restriction fragment length polymorphism (PCR-RFLP) 
 The PCR products of the CYP2C9 exon 1 was subjected to RFLP 
using 2Units of SaU96I restriction enzyme with NEB buffer 4 at 37˚C 
overnight to analyze the CYP2C9*2 genetic variant.  
Content 
For 20ul 
Reaction 
Final 
Concentration 
PCR product 10 - 
SaU96 I Enzyme 0.4 2 Units 
10X NEB buffer 4 2 1X 
D. H2O 7.6 - 
 
 Restriction digested PCR products were run in 2% Agarose gels made 
with 1X  TAE and run at 100 V for 30 min using 1X TAE as running buffer 
in Mupid Ex (Takara, Japan) electrophoresis unit.  Gels were stained with 
Ethidium Bromide and photographed using Gel documentation system (UV 
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Tech, USA).  The genetic variants were identified based on the restriction 
pattern of PCR product. 
Recognition sequence of SaU96I restriction enzyme is altered due to the 
CYP2C9 *2 variant (430C>T). 
 
Digestion pattern of the CYP2C9*2 allele 
Allele CC CT TT 
Digestion pattern 
(bp) 
 473 473 
305 305  
168 168  
 
Primers used to amplify CYP2C9 exon 4 region to study *3, *4, *5 
variants 
>chr10:96740964+96741219  (256bp)  
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GTGTGATTGGCAGAAACCGGAGCccctgcatgcaagacaggagccacatgccctacac
aga 
tgctgtggtgcacgaggtccagagatacA*3T*4tgaC*5cttctccccaccagcctgccccatgcagtgacc
tgtgacattaaattcagaaactatctcattcccaaggtaagtttgtttctcctacactgcaactccatgttttcgaagt
ccccaaattcatagtatcatttttaaaCCTCTACCATCACCGGGTGAGA 
 
To avoid interference from family members like CYP2C19) the 
following internal reverse primer was used for Sequencing CYP2C9 exon4 
PCR product.  
5`- GATACTATGAATTTGGGGACTTCG -3` 
SEQUENCING  
 The PCR products were sequenced through a commercial service 
provider Macrogen Inc. South Korea using the regular forward primers and 
an internal reverse primer specific to CYP2C9. The sequencing chromogram 
was read at BioEdit V 7.0.9.0 Software.   
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RESULTS 
  In total 50 confirmed DVT cases were recruited for the study.  Blood 
Samples were collected and DNA was isolated and analyzed for the CYP2C9 
*2, *3, *4 and *5. 
Demographic features of study population 
Age 
Among the 50 cases of DVT selected in our study group, 32% were in 
the age group of 18-35 years and 54% were in the age group 36-55 years and 
14% were in the age group of 56-80 years  
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Sex 
In this study group 54% of the cases were males and 46% were 
females. The incidence of the disease was seen more in the 36-60 years age 
group in both the sex. 
 
 Distribution cases based on the sex 
 
Smoking and Alcohol use 
 There was no history of smoking among females and 92% of 
males were smokers and among the smokers 52% of them were also 
alcoholic. 
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Smoking distribution in the DVT cases 
 
 
Etiological factors of the study group 
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 Causes for DVT may be primary and secondary. Secondary causes 
includes trauma, immobilization, surgeris ,malignancies. Various etiologies 
are shown in the following  
 
 
 
Secondary causes of the DVT cases 
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Secondary DVT due to malignancy 
In our study group, 32 cases presented with left lower limb DVT and 
18 cases presented with right lower limb DVT.  
 
DNA isolation 
DNA was successfully isolated from all the DVT cases. The quantity 
and purity of DNA samples were found to be good (purity ranging from 1.8-
2.0).  
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UV SPECTROMETER SCAN 
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Agarose gel electrophoresis of Genomic DNA 
The quality of DNAs was checked in 1% Agarose gel running at 100 V 
for 30 min in 1X TAE buffer and it was found to be intact high molecular 
weight DNA. 
 
Genomic DNA Agarose Gel Electrophoresis (0.7% Agarose at 100 volts) 
PCR amplification 
CYP2C9 exon 1 and 4 were amplified with the sequence specific primers 
resulting in 473 bp  and 256 bp respectively.  Out of 50 samples 8 were not 
amplified in PCR  and this may be due to presense of heparin in DNA 
preparation. Agarose gel electrophoresis of PCR amplified CYP2C9 exon 1 
region covering the *2 variant (under the conditions 2% Agarose in 0.5X 
TAE at 100 Volts)        
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CYP2C9 PCR Exon 1 Product. 
 
 
 
 
 
Restriction Fragment Length Polymorphism 
Expected digestion pattern of the CYP2C9*2 allele 
Allele CC (WT) CT (HT) TT 
Digestion pattern 
(bp) 
 473 473 
305 305  
168 168  
 
CYP2C9*2 variant was screened by PCR-RFLP using restriction enzyme 
Sau 69I. Out of 42 DNA samples 37 of them found to be wild type and only 5 
cases were heterozygous for *2 mutation 
 
 
 
 
473 bp 
305 bp 
168 bp 
HT WT 
473 bp 
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 RFLP pattern of CYP2C9 exon 1 covering *2 variant. Agarose gel 
electrophoresis of Sau 69I digested CYP2C9 exon 2 (under the conditions 2% 
Agarose in 0.5X TAE at 100 Volts) 
 
 
 
 
 Agarose gel electrophoresis of PCR amplified CYP2C9 exon 4 region for 
*3, *4 and *5 variants (under the conditions 2% Agarose in 0.5X TAE at 100 
Volts) 
DNA sequencing 
CYP2C9 *3 *4 *5 variants were identified by DNA sequencing of 
exon 4.Internal primer was used for sequencing to avoid interference from the 
family genes. All the 42 cases sequenced for *3,*4,*5 variants were found to 
be wild type (fig). In summary out of 42 cases analyzed only 5 were found to 
be heterozygous. 
256 bp 
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Sequencing Chromogram of CYP2C9 exon 4 showing wild type sequence 
for the *3, *4, and *5 
Distribution of CYP2C9 *2,*3, *4, and *5 genetic variants in the current 
study population 
 
 
 
 
    *5                  *3 *4 
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Multiple alignment of DNA sequences showing the wild type genotype of 
CYP2C9 *3,*4, and *5 
*5 
*4 
*3 
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DISCUSSION 
Deep vein thrombosis occurs most often in the large veins of the legs 
such as the femoral vein or the popliteal vein and it is the one of the leading 
cause of morbidity and mortality. Deep vein thrombosis if not treated will 
/can lead to a life threatening pulmonary embolism. Warfarin is a hydroxyl 
coumarin derivative widely used as an anticoagulant for treating DVT 
patients with a narrow therapeutic index and wide inter-individual variability 
in dose requirement with the risk of thromboembolism or bleeding depending 
on underdosing or overdosing respectively.  
Genetic variations in the VKORC1 and CYP2C9 have been shown to 
account for 30-50% of the variability in the required dosage of warfarin. 
Genetic variations of CYP2C9 are responsible for the pharmacokinetic effect 
on warfarin metabolism. Individuals with the CYP2C9*2 and CYP2C9*3 
polymorphisms have decreased clearance of S-warfarin and therefore also an 
increased plasma concentration ratio when compared to R-warfarin. In 
patients with allelic variants the relative concentration of S-warfarin increases 
in patients homozygous for the CYP2C9*3 polymorphisms.  The Genetic 
screening of VKORC1 and CYP2C9 polymorphisms may help in better and 
effective clinical management. 
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This pilot study was aimed to study the frequency of the CYP2C9*3 
polymorphism rs1057910 along with associated polymorphisms (CYP2C9*3 
(rs1057910), *4 (rs1057909) and *5 (rs28371686) in south in Indian DVT 
patients (n=50). Out of 50 DVT blood samples collected DNA isolation and 
sequencing was successful for 42 samples. CYP2C9*2 (rs1799853) variants 
was found in 5 patient samples in heterozygotes CT (11.9%) state. No 
homozygous mutant allele for CYP2C9*2 (rs1799853) was observed. The 
CYP2C9*2 (rs1799853) heterozygote may require less warfarin (in the 
medium range 4 mg). All the remaining patients with CYP2C9 wild type 
allele may be given the maximum dosage without the risk of bleeding. 
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SUMMARY AND CONCLUSION 
1. Inter-individual variation in the effect of anticoagulants makes the 
treatment and management of DVT a challenging task. 
2. Inappropriate dosing may results in adverse effects like under 
treatment or over treatment causing life threatening complication like 
bleeding. 
3. Genetic variations in VKORC1 and CYP2C9 were shown to influence 
the dose requirement of Warfarin. 
4. Fifty Deep vein thrombosis patients with primary and secondary DVT 
were recruited for the study with varying age group and appropriate 
exclusion criteria. 
5. CYP2C9 genetic variants *2, *3, *4 and *5 were analyzed in 42 cases 
successfully. Out of 42 samples analyzed 5 samples were found to be 
heterozygous for CYP2C9 *2 variant. 
6. All other cases were found to carry wild type alleles for all the genetic 
variants analyzed in this study. 
7. The cases having CYP2C9 *2 heterozygous variant require decreased 
dose of warfarin by approximately 20-30% compared to CYP2C9 wild 
type individuals. 
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LIMITATIONS OF THE STUDY 
Testing with more number of samples will identify the frequency of 
these CYP2C9 genetic variants *2, *3, *4 and *5 in south Indian population 
and may help in better and effective clinical management.  This study should 
be extended to analyze the associated VKORC1 genetic variants and to 
suggest the appropriate dosage based on the genetic study.   
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ABBREVIATIONS 
 
DVT    Deep vein thrombosis 
PE                                     Pulmonary embolism 
VTE                                  Venous thromboembolism 
HIF-1                                Hypoxia inducible factor-1 
ELISA                               Enzyme linked immunosorbent assay 
SLE                                   Systemic lupus erythematosus  
HIT                                   Heparin induced thrombocytopenia 
AT                                    Antithrombin 
RE SYSTEM                    Reticulo endothelial system 
VKORC1                          Vitamin K epoxy reductase complex 
PT                                     Prothrombin time 
INR                                   International Normalized Ratio 
ICH                                   Intra cerebral haemorrhage 
LMWH                             Low molecular weight heparin 
  
 
S.No IP.No Name of Patient Age Sex Smoking/AlchocolDVT Side Level Etiology Risk Factor Duration of Symptoms
DVT1 8350 Annammal 60 F - Right I liofemoral Secondary Cervical Cancer Stage III / immobolization1 month
DVT2 9289 Kaleem 34 M S/A Left I liofemoral Primary - 15 days
DVT3 9599 Lakshmi 47 F - Right Femoropopliteal Secondary CaCx 5 days
DVT4 10606 Mahesh 65 M S Right I liofemoral Primary Suspected Malignancy, Generalized lymphadenopathy1 week
DVT5 10623 Balakrishnan 65 M S Left I liofemoral Primary - 1.5 month
DVT6 10847 Mangaiyarkarasi 55 F - Left I liofemoral Primary - 1 week
DVT7 13328 Shak Abbas 28 M S/A Right I liofemoral Primary - 5 days
DVT8 13390 Lakshmi 42 F - Left I liofemoral Primary - 1 month
DVT9 17038 Thirupathy 40 M S/A Right I liofemoral Primary - 1 week
DVT10 16787 Mahendran 55 M S Left I liofemoral Primary 20 days
DVT11 15963 Govindan 70 M S/A Left I liofemoral Primary 2 months
DVT12 17026 Manivannan 35 M S/A Left Femoropopliteal Primary - 10 days
DVT13 Palani 45 M S Right I liofemoral Secondary Trauma 10 days
DVT14 20873 Govindaraj 55 M S Left I liofemoral Secondary Malignancy 4 days
DVT15 18669 Rajan 45 M S Right Calf Vein Primary Swelling in legs 1 month
DVT16 18677 Kala 50 F - Right I liofemoral Secondary Malignancy 10 days
DVT17 18694 Murugan 27 M S Right I liofemoral Primary Immobolization 2 weeks R/ 4 months L
DVT18 19667 Rajammal 50 F - Left I liofemoral Primary Swelling in legs 15 days
DVT19 21170 Valarmathy 36 F - Left I liofemoral Primary Fioroid Utereus 4 days
DVT20 28786 Mahalaxmi 42 F - Left I liofemoral Secondary Heptoectomy 10 days
DVT21 1896-10 Kalaivani 20 F - Left Calf Vein Secondary Trauma
DVT22 42036 Shanthi 40 F - Left Secondary Varicose veins
DVT23 41071 Raguvaran 29 M S/A Left I liofemoral Primary - 2 weeks
DVT24 41854 Krishnamoorthy 53 M S/A Left Femoropopliteal Primary - 10 days
DVT25 40652 Mani 42 M S Left l liofemoral Secondary Trauma 5 days
DVT26 37959 Rathinaraj 45 M S/A Left I liofemoral Primary Trauma, immobolization 2 weeks
DVT27 35841 Selvi 23 F N Left I liofemoral Secondary LSCS 10 days
DVT28 35788 Lakshmi 35 F - Left I liofemoral Primary - 2 weeks
DVT29 43663 Vasantha 55 F - Left I liofemoral Secondary Trauma, immobolization 15 days
DVT30 43106 Gopalakrishnan 60 M S Right I liofemoral Primary - 10 days
DVT31 37290 Maheswari 40 F - Left I liofemoral Primary - 10 days
DVT32 59494 Guna 29 F - Left I liofemoral Secondary immobolization 10 days
DVT33 59517 Prabhakaran 38 M S Left Primary - 5 days
DVT34 58164 Malarvizhi 23 F - Right I liofemoral Secondary Varicose veins 7 days
DVT35 53254 Nateesa 27 F - Bilateral I liofemoral Secondary immobolization 2 days L / 1 month R
DVT36 57718 Ravichandran 46 M S/A Right I liofemoral Primary - 2 weeks
DVT37 59461 Velankanni 35 M S/A Left I liofemoral Primary - 1 month
DVT38 57098 Murugananthan 42 M S/A Left I liofemoral Primary - 10 days
DVT39 54902 Sumathy 19 F - Left I liofemoral Secondary immobolization, Post operative LSCS5 days
DVT40 62426 Sanjeev Reddy 51 M S Right I liofemoral Primary - 1 week
DVT41 62615 Ramya 23 F - Left I liofemoral Secondary LSCS 1 week
DVT42 63079 Chinnadurai 21 M S/A Left Femoropopliteal Primary - 5 days
DVT43 67410 Saamanthi 86 F
DVT44 65402 Saroja 60 F
DVT45 65675 Shyamala 42 F
DVT46 62656 Sekar 40 M
DVT47 67514 Arumugam 43 M S/A Left I liofemoral Primary - 5 days
DVT48 67823 Kavitha 31 F - Left Femoropopliteal Primary - 5 days
DVT49 68732 Mohammed Abdul Sabu39 M - Right I liofemoral Primary - 2 weeks
DVT50 69018 Selvam 44 M S/A Left I liofemoral Secondary Trauma 10 days
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We are conducting a study on “SCREENING OF CYP450 2C9 GENETIC 
POLYMORPHISM ASSOCIATED WITH ACENOCOUMAROL SENSITIVITY IN 
DVT CASES” among patients attending Rajiv Gandhi Government General Hospital, 
Chennai and for that your specimen may be valuable to us. 
The purpose of this study is to screen the genetic polymorphism of the acenocoumarol 
metabolizing enzyme CYP450 2C9. 
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specimen to perform studies which in any way do not affect your final report or management. 
The privacy of the patients in the research will be maintained throughout the study. In 
the event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to participate in 
this study or to withdraw at any time; your decision will not result in any loss of benefits to 
which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the study period 
or during the study if anything is found abnormal which may aid in the management or 
treatment. 
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